Multiplex Assay Market Regional Analysis

Multiplex Assay Market size was valued at USD 2.7 Billion in 2023 and is poised to grow from USD 3.1 Billion in 2024 to USD 9.32 Billion by 2032, growing at a CAGR of 14.77% during the forecast period (2025-2032).

To increase their market presence, leading corporations are putting a variety of methods into practice, including partnerships, the introduction of cutting-edge technology & goods, and collaborations. For instance, Bio-Rad and Seegene announced their collaboration in June 2021 in order to offer molecular diagnostic testing solutions in the American market. Additionally, Qiagen introduced the NeuMoDx multiplex assay in November 2020 to offer a comprehensive selection of testing options for SARS-CoV-2 in Europe and international markets. 'Illumina, Inc. (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Thermo Fisher Scientific, Inc. (US) ', 'Becton, Dickinson and Company (US) ', 'DiaSorin S.p.A. (Italy) ', 'QIAGEN N.V. (Netherlands) ', 'Abcam PLC (UK) ', 'Merck KGaA (Germany) ', 'Agilent Technologies, Inc. (US) ', 'Quanterix (US) ', 'Bio-Techne (US) ', 'Meso Scale Diagnostics, LLC (US) ', 'Randox Laboratories Ltd. (UK) ', 'Olink (Sweden) ', 'Seegene Inc. (South Korea) ', 'Siemens Healthineers AG (Germany) ', 'PerkinElmer Inc. (US) ', 'Shimadzu Corporation (Japan) ', 'Promega Corporation (US) ', 'Enzo Biochem Inc. (US) ', 'Cayman Chemical (US) ', 'Boster Biological Technology (US) ', 'Antigenix America, Inc. (US) ', 'Quansys Biosciences Inc. (US) ', 'RayBiotech Life, Inc. (US) '

Increasing Demand for Personalized Medicine 

Increasing adoption of multiplex immunoassays: The demand for multiplex immunoassays is increasing due to their ability to measure multiple proteins in a single sample. These assays are widely used in drug discovery, diagnostic testing, and biomarker identification.

North America dominated the global industry in 2023 and accounted for the largest share of more than 36.88% of the total revenue because of the rising R&D activities for the discovery of novel medications and diagnosis & treatment options. The region's expansion is anticipated to be fueled by the rise in government funding for the discovery of new biomarkers and the rise in the prevalence of chronic illnesses like cancer and stroke. Additionally, the presence of significant players in the region is likely to boost the rise.